The Board of Resonance Health announced that the company has executed two multi-year contracts with pharmaceutical companies for undisclosed sums. Both trials are scheduled to commence in the first quarter of 2018, with the Company expanding its capabilities to provide Contract Research Organization (CRO) services. The first of the studies will evaluate the efficacy and safety of a potential new therapy to address patients with transfusion-dependent beta-thalassemia. The second will investigate the efficacy and safety of a new treatment for patients requiring regular blood transfusions.